Phase III
An investigational medicine in late-stage development by Jazz Pharmaceuticals hit the mark in treating cataplexy and excessive daytime sleepiness in adults with narcolepsy.
It was a moderately busy week for clinical trial news. Here’s a look.
Inclisiran is the first and only drug for cholesterol in the siRNA class.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced multiple data presentations from its solid tumour portfolio, including key prostate cancer data, will be featured at the European Society for Medical Oncology 2019 Annual Congress, taking place 27th September to 1st October in Barcelona, Spain.
Shares of Zealand Pharma A/S are climbing in premarket trading after the company posted another late-stage success for dasiglucagon in treating severe hypoglycemia.
RESCUE and REVERSE are two separate but parallel Phase III trials evaluating the efficacy of a single intravitreal injection of GS0101 in patients with LHON from the G11778A mutation in the mitochondrial ND4 gene.
Ipsen announced positive data from the ENGAGE Phase IIIb/IV clinical trial of Dysport (abobotulinumtoxinA) to treat upper and lower limb spasticity in adults with a Guided Self-rehabilitation Contract.
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
While the approval of AveXis’ gene therapy for spinal muscular atrophy has been tainted by the revelation of early data manipulation, the Novartis subsidiary presented some long-term data at a conference that backs up the treatment’s efficacy.
AveXis presented new interim data from the Phase III SPR1NT trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.
PRESS RELEASES